방사선종양학

본문글자크기
  • 2017년 10월호
    [Clin Cancer Res.] In Situ Vaccination after Accelerated Hypofractionated Radiation and Surgery in a Mesothelioma Mouse Model.

    Toronto General Hospital / Marc de Perrot*

  • 출처
    Clin Cancer Res.
  • 등재일
    2017 Sep 15
  • 저널이슈번호
    23(18):5502-5513. doi: 10.1158/1078-0432.CCR-17-0438. Epub 2017 Jun 12.
  • 내용

    바로가기  >

    Abstract


    Purpose: 

    How best to sequence and integrate immunotherapy into standard of care is currently unknown. Clinical protocols with accelerated nonablative hypofractionated radiation followed by surgery could provide an opportunity to implement immune checkpoint blockade.

     

    Experimental Design: 

    We therefore assessed the impact of nonablative hypofractionated radiation on the immune system in combination with surgery in a mouse mesothelioma model. Blunt surgery (R1 resection) was used to analyze the short-term effect, and radical surgery (R0 resection) was used to analyze the long-term effect of this radiation protocol before surgery.

     

    Results:

    Nonablative hypofractionated radiation led to a specific immune activation against the tumor associated with significant upregulation of CD8+ T cells, limiting the negative effect of an incomplete resection. The same radiation protocol performed 7 days before radical surgery led to a long-term antitumor immune protection that was primarily driven by CD4+ T cells. Radical surgery alone or with a short course of nonablative radiation completed 24 hours before radical surgery did not provide this vaccination effect. Combining this radiation protocol with CTLA-4 blockade provided better results than radiation alone. The effect of PD-1 or PD-L1 blockade with this radiation protocol was less effective than the combination with CTLA-4 blockade.

     

    Conclusions: 

    A specific activation of the immune system against the tumor contributes to the benefit of accelerated, hypofractionated radiation before surgery. Nonablative hypofractionated radiation combined with surgery provides an opportunity to introduce immune checkpoint blockades in the clinical setting.

     

    Author information

    De La Maza L1, Wu M1, Wu L1, Yun H1, Zhao Y1, Cattral M2, McCart A2, Cho BJ3, de Perrot M4,5.

    Latner Thoracic Surgery Research Laboratories, Toronto General Research Institute, University of Toronto, Toronto, Ontario, Canada.

    Department of General Surgery, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada.

    Department of Radiation Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.

    Latner Thoracic Surgery Research Laboratories, Toronto General Research Institute, University of Toronto, Toronto, Ontario, Canada. marc.deperrot@uhn.ca.

    Division of Thoracic Surgery, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. 

  • 덧글달기
    덧글달기
       IP : 3.139.82.23

    등록